Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mavyret Clear all
Not listed Phase 4 Interventional

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

NCT03364725
View directory record Official record
Conditions
Hepatitis C, Addict Heroin
Interventions
Glecaprevir-pibrentasvir
Drug
Lead sponsor
Id Care
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

NCT03627299
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

NCT03523871
View directory record Official record
Conditions
Hepatitis C
Interventions
Mavyret
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 18, 2026, 2:09 AM EDT
Recruiting No phase listed Observational

Feasibility and Acceptability of HCV Treatment in Pregnancy

NCT06367465
View directory record Official record
Conditions
Hepatitis C, Pregnancy Complications
Interventions
Glecaprevir-pibrentasvir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Timeline
2024 – 2026
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

NCT03117569
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
glecaprevir (300mg)/pibrentasvir (120mg)
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

NCT02939989
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
8
States / cities
Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional

Glecaprevir/Pibrentasvir for the Treatment of PTSD

NCT05446857
View directory record Official record
Conditions
PTSD
Interventions
Glecaprevir / Pibrentasvir Pill
Drug
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 18, 2026, 2:09 AM EDT
Terminated Phase 4 Interventional Results available

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

NCT04515797
View directory record Official record
Conditions
Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions
Glecaprevir and Pibrentasvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

NCT02743897
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Zepatier, Mavyret
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 18, 2026, 2:09 AM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

NCT03801707
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C, HCV
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Not applicable Interventional Results available

Rapid HCV Treatment Access for Persons Who Use Drugs

NCT04677153
View directory record Official record
Conditions
Hepatitis C Virus Infection, Response to Therapy of
Interventions
Test and treat plus peer mentors, Usual care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

NCT04575896
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 18, 2026, 2:09 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

HCV Test and Treat Utilizing Simplified HCV Patient Education

NCT05582681
View directory record Official record
Conditions
Hepatitis C
Interventions
Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir
Diagnostic Test · Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Long Island City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

NCT02966795
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 18, 2026, 2:09 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

NCT03212521
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 18, 2026, 2:09 AM EDT
Not listed Not applicable Interventional

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

NCT03164902
View directory record Official record
Conditions
Hepatitis C, Chronic, Nonadherence, Patient
Interventions
Digital Medicine
Device
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 18, 2026, 2:09 AM EDT
Withdrawn Phase 4 Interventional

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

NCT04235049
View directory record Official record
Conditions
HCV Infection
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Not applicable Interventional

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

NCT05108935
View directory record Official record
Conditions
Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions
Suboxone, Truvada, Mavyret
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Early Phase 1 Interventional

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

NCT04682509
View directory record Official record
Conditions
ESRD
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 18, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 18, 2026, 2:09 AM EDT